Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 24 09:34AM ET
4.55
Dollar change
-0.19
Percentage change
-4.01
%
Index- P/E- EPS (ttm)- Insider Own18.87% Shs Outstand28.23M Perf Week-36.01%
Market Cap148.88M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float26.55M Perf Month-57.67%
Income- PEG- EPS next Q- Inst Own1.47% Short Float0.52% Perf Quarter-62.05%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio1.00 Perf Half Y-
Book/sh-0.12 P/B- EPS next Y- ROA- Short Interest0.14M Perf Year-
Cash/sh0.25 P/C18.24 EPS next 5Y- ROE- 52W Range3.99 - 55.00 Perf YTD-84.36%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-91.73% Beta-
Dividend TTM- Quick Ratio0.64 Sales past 5Y0.00% Gross Margin- 52W Low14.04% ATR (14)1.37
Dividend Ex-Date- Current Ratio0.64 EPS Y/Y TTM- Oper. Margin- RSI (14)30.10 Volatility23.10% 19.69%
Employees10 Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom- Target Price-
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q-437.63% Payout- Rel Volume0.37 Prev Close4.74
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume138.62K Price4.55
SMA20-49.65% SMA50-53.32% SMA200-57.88% Trades Volume3,046 Change-4.01%
Jun-13-24 09:31AM
Jun-06-24 09:31AM
May-15-24 04:30PM
09:54AM
May-14-24 05:24PM
09:31AM Loading…
May-07-24 09:31AM
Apr-25-24 08:00AM
Apr-11-24 09:31AM
Apr-04-24 09:31AM
Mar-28-24 09:31AM
Mar-19-24 09:31AM
Mar-13-24 09:31AM
Mar-06-24 09:31AM
Feb-29-24 05:44PM
Feb-20-24 09:31AM
09:31AM Loading…
Feb-13-24 09:31AM
Feb-08-24 09:31AM
Feb-06-24 09:31AM
Jan-31-24 10:00AM
FibroBiologics, Inc. engages in the development and commercialization of cell therapies. It focuses on treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The firm's product pipeline includes CybroCell, CYMS101, CYWC628, TCB190, and CYTER915. The company was founded by Peter O'Heeron on April 8, 2021 and is headquartered in Houston, TX.